Cited by 238Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Genomics and Diagnostics

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Genetic alterations in bladder cancer

Dalbagni, G., Presti, J., Fair, W.R., Reuter, V., Cordon-Cardo, C.·1993·The Lancet

Open this paper in CoChat — free account

Abstract

To see whether genetic alterations follow a sequence of events leading to bladder cancer progression, 60 paired bladder tumours and normal tissues were analysed with polymorphic DNA markers, correlating loss of heterozygosity (LOH) at candidate tumour suppressor gene sites with pathological indices of poor clinical outcome. Distinct genotypic patterns were associated with early and late stages of bladder cancer. 9q deletions were observed in all superficial papillary tumours (Ta) and almost all tumours invading the lamina propria (T1), suggesting that this event associates with the development of superficial bladder tumours. However, 3p, 5q, and 17p deletions were absent in the Ta tumours but were identified in invasive bladder cancers. Two genetic pathways characterise the evolution of superficial bladder tumours. 9qLOH was detected in most Ta tumours, but in only 43% of muscle invasive neoplasms. Our hypothesis is that certain chromosomal abnormalities have a defined role in bladder tumour development, whereas others correlate with pathological indices of poor clinical outcome.

Integrity signals

Registry

Crossref · 10.1016/0140-6736(93)91595-d

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Identification of FAP Locus Genes from Chromosome 5q21
Kinzler, K. W., Nilbert, M. C., Su, L.-K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hedge, P., McKechnie, D., et al. (1991) · Science · doi:10.1126/science.1651562 · Cited by 2,331
Allelotype of Colorectal Carcinomas
Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C., Nakamura, Y., & White, R. L. (1989) · Science · doi:10.1126/science.2565047 · Cited by 1,302
Location of gene for Gorlin syndrome
Farndon, P. A., Mastro, R. G. D., Kilpatrick, M. W., & Evans, D. G. (1992) · The Lancet · doi:10.1016/0140-6736(92)90868-4 · Cited by 397
Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer
Cordon‐Cardo, C., Wartinger, D. D., Petrylak, D. P., Dalbagni, G. M., Fair, W. R., FUKS, Z. Y., & Reuter, V. E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1251 · Cited by 334
Self-citation
Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer
Logothetis, C. J., Xu, H., Ro, J. Y., Hu, S., Şahin, A., Ordóǹez, N. G., & Benedict, W. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1256 · Cited by 244
Molecular genetic alterations in superficial and locally advanced human bladder cancer.
Presti, J. C., Reuter, V. E., Galan, T. I., Fair, W. R., & Cordón-Cardó, C. (1991) · PubMed · Cited by 230
Self-citation
Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q.
Devilee, P., van Vliet, M., van Sloun, P., Kuipers‐Dijkshoorn, N. J., Hermans, J., Pearson, P. L., & Cj, C. (1991) · PubMed · Cited by 195
Cytogenetic Studies of Carcinoma in Situ of the Bladder: Prognostic Implications
Tyrkus, M., Powell, I. J., & Fakr, W. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)36504-7 · Cited by 38

Show all 9 references

Sorted by citations

Items 101–200 of 238

Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status
Kang, H. W., Kim, Y., Jeong, P., Park, C., Kim, W. T., Ryu, D. H., Cha, E., Ha, Y., Kim, T., Kwon, T. G., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6621 · Cited by 38
Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo‐Romero, J. G., Sánchez, A. S. S., Bachs, J. M. G., Sánchez‐Sánchez, F., Escribano, J., Segura-Martín, M., Millán, I. H., & Virseda‐Rodriguez, J. A. (2003) · PubMed · doi:10.1097/01.ju.0000046224.57330.70 · Cited by 38
Genetics of bladder cancer
Saran, K. K., Gould, D., GODEC, C. J., & Verma, R. S. (1996) · Journal of Molecular Medicine · doi:10.1007/bf00217519 · Cited by 38
Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder.
Cheng, J. Q., Huang, H., Pak, J., Shapiro, E., Sun, T., Cordon‐Cardo, C., Waldman, F. M., & Wu, X. (2003) · PubMed · Cited by 38
Self-citation
Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations.
Zhang, F. F., Arber, D. A., Wilson, T. G., Kawachi, M. H., & Slovak, M. L. (1997) · PubMed · Cited by 38
High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 ( MDM4 ) as an Amplification Target Exclusive of MDM2 and TP53
Veerakumarasivam, A., Scott, H. E., Chin, S., Warren, A. Y., Wallard, M. J., Grimmer, D., Ichimura, K., Caldas, C., Collins, V. P., Neal, D. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4129 · Cited by 38
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
DeFazio, A., Chiew, Y.-E., Sini, R. L., Janes, P. W., & Sutherland, R. L. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4 · Cited by 136
Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman, I., Scher, H. I., Zhang, Z., Pellicer, I., Hamza, R., Eissa, S., Khaled, H. M., & Cordon‐Cardo, C. (1997) · PubMed · Cited by 36
Self-citation
Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging
Sugano, K., & Kakizoe, T. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0649 · Cited by 36
Cytogenetics of bladder cancer
Gibas, Z., & Gibas, L. M. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00295-6 · Cited by 36
Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data
Bulashevska, S., Szakács, O., Brors, B., Eils, R., & Kovács, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.20180 · Cited by 35
p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer
Sengeløv, L., Horn, T. D., & Steven, K. (1997) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050106 · Cited by 35
Mapping and Genome Sequence Analysis of Chromosome 5 Regions Involved in Bladder Cancer Progression
Kram, A., Li, L., Zhang, R. D., Yoon, D. S., Ro, J. Y., Johnston, D. A., Grossman, H. B., Scherer, S. E., & Czerniak, B. A. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780315 · Cited by 34
Loss of expression of thep16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage
Talve, L., Sauroja, I., Collan, Y. U., Punnonen, K. R. A., & Ekfors, T. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970620)74:3 · Cited by 111
Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma
Tang, H., Jiang, L., Zhu, C., Liu, R., Wu, Y., Yan, Q., Liu, M., Jia, Y., Chen, J., Qin, Y., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0648-7 · Cited by 33
Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression
Sänchez‐Carbayo, M., Socci, N. D., Richstone, L., Cortón, M., Behrendt, N., Wulkfuhle, J., Bochner, B. H., Petricoin, E. F., III, & Cordon‐Cardo, C. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070338 · Cited by 32
Self-citation
Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53 -Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas
He, F., Melamed, J., Tang, M., Huang, C., & Wu, X. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3067 · Cited by 31
Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder
Konety, B. R., & Williams, R. D. (2004) · British Journal of Urology · doi:10.1111/j.1464-410x.2003.04894.x · Cited by 31
Prognostic Implications of p53 Gene Mutations in Bladder Tumors
Lorenzo‐Romero, J. G., Sánchez, A. S. S., Bachs, J. M. G., Sánchez‐Sánchez, F., Escribano, J., Segura-Martín, M., Millán, I. H., & Virseda‐Rodriguez, J. A. (2003) · The Journal of Urology · doi:10.1016/s0022-5347(05)63941-9 · Cited by 30
Recent developments in the pathophysiology of bladder cancer.
Rozanski, T. A., & Grossman, H. B. (1994) · American Journal of Roentgenology · doi:10.2214/ajr.163.4.8092012 · Cited by 30
Analysis of genomic instability in squamous cell carcinoma of the head and neck using the random amplified polymorphic DNA method
Maeda, T., Jikko, A., Hiranuma, H., & Fuchihata, H. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00004-x · Cited by 30
Transitional cell carcinoma expresses high levels of Fas ligand in vivo
Lee, Lee, Park, Kim, Jang, & Yoo (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00975.x · Cited by 30
A Common MicroRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ with Normal Umbrella Cells
Jia, A. Y., Castillo-Martín, M., Domenech, J. M. D., Bonal, D. M., Sänchez‐Carbayo, M., Silva, J. M., & Cordon‐Cardo, C. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.006 · Cited by 29
Self-citation
Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA
López, V., González‐Peramato, P., Suela, J., Serrano, Á., Ferran Algaba, B., Cigudosa, J. C., Vidal, A., Joaquim Bellmunt, B., Zorzo, Ó. H., & Sänchez‐Carbayo, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-182 · Cited by 29
Role of multidrug-resistance protein 2 in glutathioneS-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells
Morrow, C. S., Smitherman, P. K., & Townsend, A. J. (2000) · Molecular Carcinogenesis · doi:10.1002/1098-2744(200011)29:3 · Cited by 65
p53-stabilizing Agent CP-31398 Prevents Growth and Invasion of Urothelial Cancer of the Bladder in Transgenic UPII-SV40T Mice
Madka, V., Zhang, Y., Li, Q., Mohammed, A., Sindhwani, P., Lightfoot, S. A., Wu, X.-R., Kopelovich, L., & Rao, C. V. (2013) · Neoplasia · doi:10.1593/neo.13704 · Cited by 29
Bladder tumor markers: from hematuria to molecular diagnostics – where do we stand?
Shirodkar, S. P., & Lokeshwar, V. B. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.7.1111 · Cited by 27
Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade.
Wada, T., Louhelainen, J., Hemminki, K., Adolfsson, J., Wijkström, H., Norming, U., Borgström, E., Hansson, J., Sandstedt, B., & Steineck, G. (2000) · PubMed · Cited by 27
Bladder Cancer Outcome and Subtype Classification by Gene Expression
Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F. L., Mehta, K. M., Devries, S., Koppie, T. M., Pejavar, S., Carroll, P. R., et al. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00864-5 · Cited by 26
Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise
Zachos, I., Konstantinopoulos, P. A., Tzortzis, V., Gravas, S., Karatzas, A. D., Karamouzis, M. V., Melekos, M. D., & Papavassiliou, A. G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.496450 · Cited by 26
Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis
Brodt, P., Fallavollita, L., Bresalier, R. S., Meterissian, S. H., Norton, C. R., & Wolitzky, B. A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970516)71:4 · Cited by 225
Self-citation
Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.
Vet, J. A. M., Witjes, J. A., Marras, S. A. E., Hessels, D., van der Poel, H. G., Debruyne, F. M. J., & Schalken, J. A. (1996) · PubMed · Cited by 26
Cigarette smoking and chromosome 9 alterations in bladder cancer.
Zhang, Z., Shu, X. M., Cordon‐Cardo, C., Orlow, I., Lü, M., Millon, T. V., Cao, P. Q., Connolly-Jenks, C., Dalbagni, G. M., LIANES, P., et al. (1997) · PubMed · Cited by 25
Self-citation
The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link
Borley, N. R., Mortensen, N. J. M., Jewell, D. P., & Warren, B. F. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200002)190:2 · Cited by 158
Bladder and Urethra
Côté, R. J., Mitra, A. P., & Amin, M. B. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3966-2.00031-x · Cited by 23
Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail
Upham, B. L., Deocampo, N. D., Wurl, B., & Trosko, J. E. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981109)78:4 · Cited by 180
Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas
Masciullo, V., Scambia, G., Marone, M., Giannitelli, C., Ferrandina, G., Bellacosa, A., Panici, P. B., & Mancuso, S. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970822)74:4 · Cited by 72
Cytogenetic Investigation of Transitional Cell Carcinomas of the Upper Urinary Tract
Cin, P. D., Roskams, T., Poppel, H. V., Balzarini, P., & BERGHE, H. V. D. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00055-2 · Cited by 21
Identification of differentially expressed genes and biological pathways in bladder cancer
Tang, F., He, Z., Lei, H., Chen, Y., Lu, Z., Zeng, G., & Wang, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8711 · Cited by 20
Should there be more molecular staging of head and neck cancer to improve the choice of treatments and thereby improve survival?
Almadori, G., Bussu, F., & Paludetti, G. (2008) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0b013e3282f6a4b0 · Cited by 19
Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target
CREW, J. P., O'Brien, T. S., & Harris, A. L. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437475 · Cited by 20
p53 and human papillomavirus dna in renal pelvic and ureteral carcinoma including dysplastic lesions
Furihata, M., Yamasaki, I., Ohtsuki, Y., Sonobe, H., Morioka, M., Yamamoto, A., Terao, N., Kuwahara, M., & Fujisaki, N. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640503 · Cited by 18
Abundance and subcellular localisation of cyclin D3 in human tumours
Bártková, J., Zemanova, M., & Bártek, J. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960126)65:3 · Cited by 61
Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo
Madka, V., Mohammed, A., Li, Q., Zhang, Y., Biddick, L., Patlolla, J. M. R., Lightfoot, S. A., Towner, R. A., Wu, X., Steele, V. E., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0199 · Cited by 17
GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: A review of 25 cases
Siddiqui, M. T., Seydafkan, S., & Cohen, C. (2014) · Diagnostic Cytopathology · doi:10.1002/dc.23131 · Cited by 17
Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer
Cordon‐Cardo, C., & Sheinfeld, J. (1997) · World Journal of Urology · doi:10.1007/bf02201982 · Cited by 17
Self-citation
Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx
Obata, A., Eura, M., Sasaki, J., Saya, H., Chikamatsu, K., Tada, M., Iggo, R. D., & Yumoto, E. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2 · Cited by 58
Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis
Ehdaie, B., & Theodorescu, D. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.7.1103 · Cited by 17
Chromosomal aberrations in early-stage bilharzial bladder cancer
Aly, M. S., & Khaled, H. M. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00527-1 · Cited by 16
Superficial Bladder Tumors in Patients under 40 Years of Age: Clinical, Prognostic and Cytogenetic Aspects
Iori, F., Dominicis, C. D., Liberti, M., Frioni, D., Vahedi, M., Leonardo, C., Nunzio, C. D., & LAURENTI, C. (2001) · Urologia Internationalis · doi:10.1159/000050992 · Cited by 16
MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCER
Duggan, B. J., Kelly, J. D., KEANE, P. F., & Johnston, S. R. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66582-2 · Cited by 16
FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma
Zhou, H., He, F., Mendelsohn, C. L., Tang, M., Huang, C., & Wu, X. (2016) · Scientific Reports · doi:10.1038/srep25596 · Cited by 15
Study of Allelic Losses on 3p, 6q, and 17p in Human Urothelial Cancer
Bernués, M., Casadevall, C., Caballín, M. R., Miró, R., Ejarque, M. J., Chéchile, G., Gelabert-Más, A., & Egozcue, J. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00248-9 · Cited by 15
Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance
Mai, K. T., Flood, T. A., Williams, P., Kos, Z., & Belanger, E. C. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1456-7 · Cited by 14
Novel recurrent structural chromosomal aberrations in primary bladder cancer.
Panani, A. D., Ferti, A. D., Raptis, S., & Roussos, C. (2004) · PubMed · Cited by 14
Chromosomal Aberrations in Bilharzial Bladder Cancer as Detected by Fluorescence In Situ Hybridization
Aly, M. S., & Khaled, H. M. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00040-0 · Cited by 14
Transgenic Mouse Models of SV40-Induced Cancer
Hudson, A. L., & Colvin, E. K. (2016) · ILAR Journal · doi:10.1093/ilar/ilw001 · Cited by 14
Prognostic significance of tumour angiogenesis in schistosoma-associated adenocarcinoma of the urinary bladder
Elsobky, E. S., Gomha, M., El‐Baz, M., Abol‐Enein, H., & Shaaban, A. A. (2002) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.01419.x · Cited by 14
Chromosomal Aberrations in Transitional Cell Carcinoma: Its Correlation with Tumor Behavior
Yü, D., Chen, H., & Chang, S.-Y. (2002) · Urologia Internationalis · doi:10.1159/000065562 · Cited by 14
Risk biomarkers and current strategies for cancer chemoprevention
Kelloff, G. J., Boone, C. W., Crowell, J. A., Nayfield, S., Hawk, E. T., Malone, W. F., Steele, V. E., Lubet, R. A., & Sigman, C. C. (1996) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1996)25+ · Cited by 170
RECENT ADVANCES IN THE MOLECULAR GENETICS OF UROGENITAL TUMORS
Yoshida, O., Habuchi, T., & Ogawa, O. (1994) · International Journal of Urology · doi:10.1111/j.1442-2042.1994.tb00001.x · Cited by 14
Loss of abh antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus
Meldgaard, P., Johnson, P. H., Langkilde, N. C., Wolf, H., & Orntoft, T. F. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630306 · Cited by 13
Applications of Molecular Diagnostics: Solid Tumor Genetics Can Determine Clinical Treatment Protocols
Cordon‐Cardo, C. (2001) · Modern Pathology · doi:10.1038/modpathol.3880294 · Cited by 13
Self-citation
MOLECULAR FOLLOWUP OF NEWLY DIAGNOSED BLADDER CANCER USING URINE SAMPLES
Shigyo, M., Sugano, K., Tobisu, K., Tsukamoto, T., Sekiya, T., & Kakizoe, T. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65753-9 · Cited by 13
Synthesis and Structure−Activity Relationships of New 1,3-Disubstituted Cyclohexanes as Structurally Rigid Leukotriene B4Receptor Antagonists
Poudrel, J.-M., Hullot, P., Vidal, J., Girard, J., Rossi, J., Müller, A., Bonne, C., Безуглов, В. В., Serkov, I. V., Renard, P., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9910573 · Cited by 13
Chromosomal aberrations in Cis and Ta bilharzial bladder cancer: A theory of pathogenesis
Khaled, H. M., Aly, M. S., & Mokhtar, N. M. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.07.015 · Cited by 12
TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.
Madka, V., Mohammed, A., Li, Q., Zhang, Y., Kumar, G., Lightfoot, S. A., Wu, X., Steele, V. E., Kopelovich, L., & Rao, C. V. (2015) · Europe PMC (PubMed Central) · Cited by 12
Genetic Aberrations of NAT2 and Chromosome 8: Their Association with Progression in Transitional Cell Carcinoma of the Urinary Bladder
Watters, A. D., Stacey, M. W., Going, J. J., Grigor, K. M., Cooke, T., Sim, E., & Bartlett, J. M. S. (2001) · Urologia Internationalis · doi:10.1159/000050995 · Cited by 12
Definition of a 1-Mb homozygous deletion at 9q32-q33 in a human bladder-cancer cell line
Fujiwara, H., Emi, M., Nagai, H., Ohgaki, K., Imoto, I., Akimoto, M., Ogawa, O., & Habuchi, T. (2001) · Journal of Human Genetics · doi:10.1007/s100380170056 · Cited by 12
Deletion mapping in squamous cell carcinomas of the esophagus defines a region containing a tumor suppressor gene within a 4-centimorgan interval of the distal long arm of chromosome 9.
Miura, K., Okita, K., Furukawa, Y., Matsuno, S., & Nakamura, Y. (1995) · PubMed · Cited by 12
Selection and Development of Biomarkers for Bladder Cancer
Hemstreet, G. P., Hurst, R. E., & Bonner, R. B. (2003) · Humana Press eBooks · doi:10.1385/0-89603-380-5:37 · Cited by 12
Mouse Models of Human Bladder Cancer as a Tool for Drug Discovery
Seager, C. M., Puzio‐Kuter, A. M., Cordon‐Cardo, C., McKiernan, J., & Abate-Shen, C. T. (2010) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1414s49 · Cited by 11
Self-citation
Use of biomarkers in epidemiology. The example of metabolic susceptibility to cancer
Vineis, P. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03286-x · Cited by 11
Urine and Bladder Washings
Renshaw, A. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5329-3.00003-7 · Cited by 11
Mutation identification DNA analysis system (MIDAS) for detection of known mutations
Bazar, L. S., Collier, G. B., Vanek, P. G., Siles, B. A., Kow, Y. W., Doetsch, P. W., Cunningham, R. P., & Chirikjian, J. G. (1999) · Electrophoresis · doi:10.1002/(sici)1522-2683(19990101)20:6 · Cited by 15
The prevalence of loss of heterozygosity in chromosome 3, including FHIT , in bladder cancer, using the fluorescent multiplex polymerase chain reaction
Wada, T., Louhelainen, J., Hemminki, K., Adolfsson, J., Wijkström, H., Norming, U., Borgström, E., Hansson, J., & Steineck, G. (2001) · British Journal of Urology · doi:10.1046/j.1464-410x.2001.02212.x · Cited by 9
Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder.
Wahab, A. H. A. A., Hi, A.-Z., Mi, E.-H., Ismail, M., & Am, E.-K. (2005) · PubMed · Cited by 9
The role of molecular techniques in preventing oral cancer and improving its poor prognosis: an illusion?
Mignogna, M. D., Fedele, S., Ruoppo, E., & Russo, L. L. (2002) · Journal of Oral Pathology and Medicine · doi:10.1034/j.1600-0714.2002.310411.x · Cited by 9
Combined seminoma/non-seminoma should be considered as intermediate grade germ cell cancer (GCC)
Oliver, R. T. D., Leahy, M. G., & Ong, J. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00021-a · Cited by 9
Biomarker Study of Primary Nonmetastatic Versus Metastatic Invasive Bladder Cancer
LIANES, P., Charytonowicz, E., Cordon‐Cardo, C., Fradet, Y., Grossman, H. B., Hemstreet, G. P., Waldman, F. M., Chew, K., Wheeless, L. L., & Faraggi, D. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)69015-5 · Cited by 9
Self-citation
Bladder cancer--genetic overview.
Halachmi, S., Madeb, R. R., Kravtsov, A., Moskovitz, B., Halachmi, N., & Nativ, O. (2001) · PubMed · Cited by 9
Allelic Loss Correlated with Tissue Specificity in Head and Neck Squamous Cell Carcinomas and the Clinical Features of Patients
Shiga, K., Matsuura, K., Tateda, M., Saijo, S., Ogawa, T., Miyagi, T., & Kobayashi, T. (2004) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.204.163 · Cited by 8
Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome
Cianciulli, A. M., Bovani, R., Leonardo, F., Antenucci, A., Gandolfo, G. M., Giannarelli, D., Leonardo, C., Iori, F., & LAURENTI, C. (2000) · International Journal of Clinical & Laboratory Research · doi:10.1007/s005990070026 · Cited by 8
Mutational analysis ofRashotspots in patients with urothelial carcinoma of the bladder
Tripathi, K., Goel, A., Singhai, A., & Garg, M. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i8.614 · Cited by 7
Molecular Genetics in Carcinoma of the Bladder
Bender, C. M., & Jones, P. A. (1998) · Medical radiology · doi:10.1007/978-3-642-60258-0_4 · Cited by 7
Renal Pathology in Wagr Syndrome
Ariel, I. M., Abeliovich, D., Bar‐Ziv, J., & Hochberg, A. (1996) · Pediatric Pathology & Laboratory Medicine · doi:10.1080/15513819609168725 · Cited by 6
Methylguanine DNA Methyl Transferase Activities, Glutathione S Transferase and Nitric Oxide in Bladder Cancer Patients
Saygılı, E. İ., Akçay, T., Dinçer, Y., Öbek, C., Kural, A. R., & Çakalir, C. (2006) · Cancer Investigation · doi:10.1080/07357900600634120 · Cited by 4
Immunohistochemical evaluation of p53 and Retinoblastoma proteins in relation to hyperthermia treatment: Results in human urothelial carcinomas
Okamura, T., Ueda, K., Hashimoto, Y., Tozawa, K., & Kohri, K. (1996) · International Journal of Hyperthermia · doi:10.3109/02656739609027687 · Cited by 4
Bladder: Transitional cell carcinoma
Huret, J. L., & Leonard, C. A. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/37566 · Cited by 4
Loss of Heterozygosity of 3p21 and 9p21 in Head and Neck Squamous Cell Carcinomas and its Prognostic Implication.
Matsuura, K., Shiga, K., Yokoyama, J., Tateda, M., Nakano, H., Saijo, S., & Takasaka, T. (1999) · Nippon Jibiinkoka Gakkai Kaiho · doi:10.3950/jibiinkoka.102.613 · Cited by 4
The DCC protein -- neural development and the malignant process
Reale, M. A. (1997) · Frontiers in bioscience · doi:10.2741/a203 · Cited by 4
Urinmarker und zellbasierte Nachweisverfahren beim Urothelkarzinom
Hakenberg, O. W. (2007) · Springer eBooks · doi:10.1007/978-3-540-31041-9_9 · Cited by 3
[Cytogenetic findings in ductal carcinoma of the breast].
Rojas‐Atencio, A., González, L., Urdaneta, K., Soto, M., Prieto‐Carrasquero, M. C., Fulcado, W., Quintero, M., Boscan, A., & Álvarez‐Nava, F. (1999) · PubMed · Cited by 3
The role of Kaposi’s sarcoma-associated herpesvirus infection in the proliferation of human bladder cancer cells
Lee, J., Jeon, H., Yoo, S., Park, J., & Lee, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4096-5 · Cited by 3
Expression of Cdk4, Cyclin D1 and Rb in exogenous wild type P16 gene transfected bladder cancer cell line
Li, L., & Tian, Y. (2003) · Colloids and Surfaces B Biointerfaces · doi:10.1016/s0927-7765(03)00114-0 · Cited by 3
The Role of Genetic Instability in the Pathogenesis and Progression of Urothelial Carcinoma
Catto, J. W. F., & Hamdy, F. C. (2005) · EAU Update Series · doi:10.1016/j.euus.2005.09.003 · Cited by 2
Cáncer de vejiga
León, M. L. V., Villaverde, R. M., Expósito, F., & Álvarez‐Mon, M. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70508-0 · Cited by 2
Harnblasenkarzinome und andere Urothelkarzinome
Zöller, G. (2010) · Springer eBooks · doi:10.1007/978-3-540-79725-8_56 · Cited by 2
Bladder Cancer: General Features
Liang Cheng, C., Antonio Lopez-beltran, B., & Bostwick, D. G. (2012) · Wiley eBooks · doi:10.1002/9781118275436.ch8 · Cited by 2
Epidemiologie, Diagnose und urinbasierte Untersuchungsverfahren beim Harnblasenkarzinom
Hakenberg, O. W. (2007) · Der Onkologe · doi:10.1007/s00761-007-1281-1 · Cited by 1

Authors: Dalbagni, G., Presti, J., Fair, W. R., Reuter, V., & Cordon-Cardo, C.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Dalbagni, G.
Presti, J.
Reuter, V.
Venue: The Lancet
Publisher: Elsevier BV
Published: 1993-08
Volume: 342
Issue: 8869
Pages: 469-471
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/0140-6736(93)91595-d
OpenAlex: W2039609330
Cited by: 238
References: 9
Citations by year: 2025: 1 · 2024: 4 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 6 · 2014: 4 · 2013: 6 · 2012: 7
FWCI: 18.33
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (NCI CA-47538)
Topics: Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: bladder cancer, loss of heterozygosity, tumor suppressor, 9q deletion, muscle-invasive bladder cancer, tumor progression, chromosomal abnormalities, 3p deletion, 5q deletion, 17p deletion, clinical outcomes
MeSH terms: Alleles, Urinary Bladder Neoplasms, Chromosome Deletion, Chromosomes, Human, Pair 13, Chromosomes, Human, Pair 17, Chromosomes, Human, Pair 3, Chromosomes, Human, Pair 5, Chromosomes, Human, Pair 9, Genotype, Heterozygote, Humans, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Genes, Tumor Suppressor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genetic alterations in bladder cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks